Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

106.45 +1.19 (+1.13%)

Official Closing Price Updated: 4:10 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

December 19, 2025

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

December 17, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

December 12, 2025

From Merck & Co., Inc.

Via Business Wire

FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)

December 04, 2025

From Merck & Co., Inc.

Via Business Wire

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

Via Investor Brand Network

Topics Government

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

December 01, 2025

From Merck Sharp & Dohme

Via Business Wire

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

From BioMedWire

Via GlobeNewswire

Merck to Participate in the Citi 2025 Global Healthcare Conference

November 26, 2025

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference

November 26, 2025

From Merck Sharp & Dohme

Via Business Wire

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

Via Investor Brand Network

Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches

November 24, 2025

From Merck & Co., Inc.

Via Business Wire

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

From BioMedWire

Via GlobeNewswire

Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer

November 21, 2025

From Merck & Co., Inc.

Via Business Wire

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

November 21, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

November 19, 2025

From Merck & Co., Inc.

Via Business Wire

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

November 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Announces First-Quarter 2026 Dividend

November 18, 2025

From Merck & Co., Inc.

Via Business Wire

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

November 18, 2025

From Merck & Co., Inc.

Via Business Wire

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

November 14, 2025

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Jefferies Global Healthcare Conference in London

November 13, 2025

From Merck & Co., Inc.

Via Business Wire

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

November 09, 2025

From Merck & Co., Inc.

Via Business Wire

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

November 08, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

November 04, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody

November 04, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

November 03, 2025

From Merck Sharp & Dohme

Via Business Wire

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

October 30, 2025

From Merck & Co., Inc.

Via Business Wire

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

Via Investor Brand Network

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

October 29, 2025

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

October 29, 2025

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.